• Publications
  • Influence
Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
ABSTRACT Induction of broadly cross-reactive neutralizing antibodies is a high priority for AIDS vaccine development but one that has proven difficult to be achieved. While most immunogens generateExpand
  • 1,025
  • 51
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Building Better Vaccines In the past few years, several highly potent, broadly neutralizing antibodies (bNAbs) specific for the gp120 envelope protein of HIV-1 have been discovered. The goal of thisExpand
  • 501
  • 25
Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection
ABSTRACT The characterization of the cross-reactive, or heterologous, neutralizing antibody responses developed during human immunodeficiency virus type 1 (HIV-1) infection and the identification ofExpand
  • 502
  • 22
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies
Eliminating key glycosylation sites on HIV envelope (Env) restores binding of the germline versions of known broadly neutralizing anti-Env antibodies.
  • 225
  • 13
  • PDF
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Most existing viral vaccines generate antibodies that either block initial infection or help eradicate the virus before it can cause disease. For HIV-1, obstacles to eliciting protective neutralizingExpand
  • 452
  • 10
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice
A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs) that can prevent infection, but it has not yet been possible to elicit these antibodies by immunization.Expand
  • 206
  • 10
  • PDF
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
Abstract Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes and neutralizing activity. WeExpand
  • 133
  • 10
Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1
Recent cross-sectional analyses of HIV-1+ plasmas have indicated that broadly cross-reactive neutralizing antibody responses are developed by 10%–30% of HIV-1+ subjects. The timing of the initialExpand
  • 285
  • 8
  • PDF
An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades
ABSTRACT SF162 is a primary (PR), non-syncytium-inducing, macrophagetropic human immunodeficiency virus type 1 (HIV-1) clade B isolate which is resistant to antibody-mediated neutralization. DeletionExpand
  • 166
  • 8
Human immunodeficiency viruses.
In the early 1980s, the appearance of skin lesions characterized by a bluish-purple discoloration in young homosexual men was noted by physicians in cities on both the East and West coasts of theExpand
  • 137
  • 8
  • PDF